Cogent Biosciences (NASDAQ:COGT) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Cogent Biosciences (NASDAQ:COGTFree Report) in a report issued on Monday morning, Benzinga reports. They currently have a $19.00 target price on the technology company’s stock.

Other analysts have also issued reports about the stock. Robert W. Baird reaffirmed a neutral rating and set a $8.00 price target (down from $14.00) on shares of Cogent Biosciences in a research report on Monday, February 26th. JPMorgan Chase & Co. lifted their price target on Cogent Biosciences from $18.00 to $20.00 and gave the stock an overweight rating in a report on Tuesday, February 27th. Citigroup boosted their price target on Cogent Biosciences from $11.00 to $13.00 and gave the stock a buy rating in a research report on Monday, February 26th. Leerink Partnrs reaffirmed an outperform rating on shares of Cogent Biosciences in a research report on Thursday, February 22nd. Finally, Needham & Company LLC reissued a buy rating and set a $18.00 target price on shares of Cogent Biosciences in a report on Wednesday, May 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $14.67.

Get Our Latest Research Report on Cogent Biosciences

Cogent Biosciences Stock Down 2.8 %

NASDAQ:COGT opened at $7.35 on Monday. Cogent Biosciences has a 52-week low of $3.67 and a 52-week high of $13.50. The stock’s 50-day simple moving average is $6.77 and its 200 day simple moving average is $6.58.

Cogent Biosciences (NASDAQ:COGTGet Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The technology company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.11). On average, analysts expect that Cogent Biosciences will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cogent Biosciences

A number of large investors have recently bought and sold shares of the company. AJOVista LLC bought a new position in shares of Cogent Biosciences in the 4th quarter valued at $45,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Cogent Biosciences by 355.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,961 shares of the technology company’s stock valued at $59,000 after acquiring an additional 7,772 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Cogent Biosciences by 234.5% in the first quarter. Russell Investments Group Ltd. now owns 10,014 shares of the technology company’s stock worth $67,000 after purchasing an additional 7,020 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in Cogent Biosciences in the third quarter valued at $99,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Cogent Biosciences by 29.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,328 shares of the technology company’s stock worth $110,000 after purchasing an additional 2,571 shares during the last quarter.

Cogent Biosciences Company Profile

(Get Free Report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

Featured Articles

Analyst Recommendations for Cogent Biosciences (NASDAQ:COGT)

Receive News & Ratings for Cogent Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogent Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.